An ancillary study of "a randomized phase 2 study of TS-1 versus CDDP+VNR for adjuvant therapy in patients with non-small cell lung cancer(UMIN000027435)" - investigation of effect prediction bio-marker for adjuvant therapy.

An ancillary study of "a randomized phase 2 study of TS-1 versus CDDP+VNR for adjuvant therapy in patients with non-small cell lung cancer(UMIN000027435)" - investigation of effect prediction bio-marker for adjuvant therapy. - LOGIK1702-A

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000027436

Enrollment

190

Registered

2017-05-22

Start date

2017-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small-cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients enrolled in LOGIK1702 2) Patients providing the written informed consent.

Exclusion criteria

Exclusion criteria: Nothing particular

Design outcomes

Primary

Measure	Time frame
/Protein expression analysis using immunohistochemical staining /Gene mutation analysis of tumor tissue specimen /Gene polymorphism analysis of tumor tissue specimen	—

Countries

Japan

Contacts

Public ContactTomoshi Tsuchiya

Nagasaki University Graduate School of Biomedical Sciences Division of Surgical Oncology,

tomoshi@nagasaki-u.ac.jp095-819-7304

Outcome results